Jeff Yass’s Forte Biosciences FBRX Stock Holding History

Jeff Yass’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8M	Buy	84,600 +61,700	+269%	+$1.46M	﹤0.01%	6741
2026 Q1	$593K	Buy	+22,900	New	+$660K	﹤0.01%	9230
2022 Q3	–	Sell	-40,308	Closed	-$1.31M	–	13441
2022 Q2	$1.31M	Buy	+40,308	New	+$1.28M	﹤0.01%	5873
2022 Q1	–	Sell	-2,560	Closed	-$137K	–	13256
2021 Q4	$137K	Sell	2,560 -8,020	-76%	-$539K	﹤0.01%	11892
2021 Q3	$783K	Buy	+10,580	New	+$5.86M	﹤0.01%	8194
2020 Q2	–	Sell	-33	Closed	-$15K	–	10324
2020 Q1	$15K	Sell	33 -7	-18%	-$2.73K	﹤0.01%	9988
2019 Q4	$8K	Sell	40 -178	-82%	-$40.3K	﹤0.01%	9561
2019 Q3	$54K	Sell	218 -18	-8%	-$27.3K	﹤0.01%	9750
2019 Q2	$591K	Buy	236 +171	+263%	+$507K	﹤0.01%	6926
2019 Q1	$263K	Sell	65 -2	-3%	-$7.73K	﹤0.01%	7435
2018 Q4	$207K	Buy	67 +5	+8%	+$21.5K	﹤0.01%	7673
2018 Q3	$360K	Sell	62 -94	-60%	-$358K	﹤0.01%	7114
2018 Q2	$545K	Buy	156 +73	+88%	+$267K	﹤0.01%	6611
2018 Q1	$371K	Sell	83 -24	-22%	-$111K	﹤0.01%	7240
2017 Q4	$410K	Buy	+107	New	+$427K	﹤0.01%	7008

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jeff Yass's FBRX Position: Q2 2026 in Review

Jeff Yass reduced its Forte Biosciences (FBRX) stake by 89% in Q2 2026, selling an estimated $2.83M and leaving 14,311 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #11016.

Jeff Yass first reported a position in FBRX in Q1 2018 and has held it in 18 quarters since. The position peaked at $3.46M in Q1 2026. 85 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

Jeff Yass held 14,311 shares of Forte Biosciences worth $304K as of Q2 2026.
Jeff Yass sold 119,183 Forte Biosciences shares in Q2 2026, an estimated $2.83M.
Forte Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11016 holding.
Jeff Yass first reported a position in Forte Biosciences in Q1 2018 and has held it in 18 quarters since.
Jeff Yass's Forte Biosciences position peaked at $3.46M in Q1 2026.
85 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.